Our Platform Technology
The Lumicell™ Direct Visualization System (DVS)* has the potential to find residual cancer undetected by standard of care that may otherwise reoccur.
The Lumicell™ DVS has potential utility in multiple solid tumor indications. Over 800 patients have been clinically evaluated in seven different cancer types in 18 leading medical centers across the United States
Lumicell Appoints Brent Palmisano Chief Commercial Officer, Builds Commercial Team
Clinical Data on Lumicell’s Direct Visualization System to Be Presented at International Conference on Surgical Cancer Care
Lumicell Completes Enrollment in the INSITE Pivotal Trial for Intraoperative Breast Cancer Detection & Removal
*CAUTION: LUMISIGHT and Lumicell Direct Visualization System (DVS) are investigational products that are limited by Federal (or United States) law to investigational use. LUMISIGHT and Lumicell DVS are not authorized for marketing for any indication in any jurisdiction.